UNASSIGNED: 34 Background: Despite a substantial effort to study the clinical significance of perineural invasion in prostate biopsies (PNIb) its prognostic significance remains controversial. The limited data on perineural invasion in radical prostatectomy (RP) specimens ( @entity3121 ) suggests that biopsy specimens inadequately represent whole gland pathology thus rendering investigation of @entity3121 even more clinically relevant. While lymphovascular invasion in pathology specimens (LVIp) has been more rigorously investigated, studies have shown conflicting results. More importantly, there has been minimal comparison of @entity3121 and LVIp in the same cohort to determine which marker is the superior prognostic factor. METHODS: We retrospectively analyzed data from 1611 @entity1 who underwent RP from 1999 to 2010 from the Duke Prostate Center database. We evaluated @entity3121 and LVIp as predictors of time to BCR by comparing hazard ratios (HR) and 95% confidence intervals (CI) using crude and adjusted proportional hazards regression models that included both variables and controlled for demographic and clinico-pathological covariates. RESULTS: A total of 1304 (81%) @entity1 had @entity3121 while only 82 (5%) @entity1 had LVIp. On crude regression, both @entity3121 (HR=3.39; 95% CI=1.94-5.84; p<0.001) and LVIp (HR=2.33; 95% CI=1.49-3.64; p<0.001) were significant predictors of adverse BCR risk. After adjusting for clinico-pathological covariates, @entity3121 remained significantly associated with increased BCR risk (HR=1.85; 95%CI =1.04-3.31; p=0.04). Specifically, @entity1 with @entity3121 were 85% more likely to experience BCR relative to @entity3121 (-) @entity1 . In contrast, LVIp was not independently associated with BCR risk (p=0.23). CONCLUSIONS: In a cohort of @entity1 who underwent RP, @entity3121 is predictive of adverse BCR outcomes independent of clinicopathological parameters that include LVIp. Consequently, LVIp is a poor predictor of BCR risk. @entity3121 may thus provide additional prognostic information for @entity1 treated with RP and its inclusion in predictive nomograms requires study. Further analyses to determine if @entity3121 is likewise associated with @entity3 and @entity5 -specific survival are warranted.

XXXX : Which is a better marker for unfavorable biochemical outcomes following prostatectomy? Results from the Duke Prostate Center Database.

@entity1 :: ('9606', 'Species') :: ['men'] @entity3121 :: ('5270', 'Gene') :: ['PNIp'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']
@entity3 :: (MESH:D009362,Disease) :: ['Perineural versus lymphovascular invasion']
